Navigation Links
Modifying an anti-cancer drug makes it more specific
Date:12/3/2007

Imatinib (marketed as Gleevec in the US and Glivec in Europe and Australia) is used to treat various cancers, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It can be used to treat these two distinct types of cancer because they are caused by related proteins tyrosine kinases. However, this lack of specificity for a single protein means that imatinib can also inhibit tyrosine kinases that mediate normal bodily functions and it has been reported that in some patients this causes a toxic effect on the heart. To address some of these problems, Ariel Fernndez and colleagues at Rice University, Houston, have engineered a modified form of imatinib (known as WBZ_4) that inhibited the tyrosine kinase behind GISTs (c-KIT) as effectively as imatinib did, and that neither inhibited the tyrosine kinase behind CML (BCR-Abl) nor had toxic effects on the heart when it was administered to mice. Importantly, WBZ_4 was as effective as imatinib at reducing tumor volume and weight in a mouse model of GISTs. As noted by George Demetri from the Dana-Farber Cancer Institute, Boston, in the accompanying commentary, this study gives hope that in the future it might be possible to construct ever-better agents that can be combined safely and effectively to manage, and eventually cure, many forms of human cancer.


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related biology technology :

1. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
2. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Web Portal Makes Organ Donation Easy
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Argonne researcher studies what makes quantum dots blink
8. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
9. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
10. BioSpecifics to Present at the 9th Annual Healthcare Conference of Acumen Bio Fin Rodman Renshaw LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing facility ... Jake Lubinski will be traveling to Germany on December 6th. Mr. Lubinski will ... to discuss the benefits of a viscoelastic total disc replacement. , AxioMed received ...
(Date:12/5/2016)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") ... Safety Monitoring Board (DSMB) for the Company,s Phase ... patients has completed a second planned safety review ... planned without any modifications. The DSMB reviewed available ... efficacy concerns were identified. The DSMB will conduct ...
(Date:12/5/2016)... Research and Markets has announced the addition of Jain ... Companies" to their offering. ... , , ... development of sequencing technologies, and their applications. Current large and ... Various applications of sequencing are described including those for genetics, ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... studies. A microbiome impact grant award has been made to Dr. Renato Polimanti ... smoking and drinking on the oral microbiome. Grant proposals have been vetted by ...
Breaking Biology Technology:
(Date:11/29/2016)... Nov. 29, 2016 BioDirection, a privately held ... for the objective detection of concussion and other traumatic ... successfully completed a meeting with the U.S. Food and ... test Pre-Submission Package. During the meeting company representatives reviewed ... a precursor to commencement of a planned pilot trial. ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
(Date:11/17/2016)... , Nov. 17, 2016  AIC announces that it has just released a ... organizations that require high-performance scale-out plus high speed data transfer storage solutions. ... ... ... Setting up a high performance ...
Breaking Biology News(10 mins):